Summary
Axon Enterprise, Inc. (AXON) reported strong revenue growth of 26.8% in fiscal year 2021, reaching $863.4 million. This growth was driven by both its TASER segment (up 19.2%) and its Software and Sensors segment (up 35.6%), with the latter showing particularly robust expansion in cloud services and evidence management solutions. Despite revenue growth, the company reported a net loss of $60.0 million for the year, primarily due to a significant increase in stock-based compensation expenses related to its CEO Performance Award and eXponential Stock Performance Plan (XSPP), alongside increased operating expenses from headcount growth and R&D investments. The company anticipates continued growth, projecting revenue of approximately $1 billion for fiscal year 2022 and is making substantial investments in its manufacturing facilities. Key areas of investment include a new manufacturing and office campus in Scottsdale, Arizona, and capacity expansion for TASER devices. Management is focused on its strategic goal of building highly recurring, highly profitable businesses and expanding its total addressable market through new products, customer segments, and geographic regions. However, investors should be mindful of potential supply chain constraints and the company's reliance on government budgets, which can introduce variability in sales cycles and contract fulfillment.
Financial Highlights
51 data points| Revenue | $865.64M |
| Cost of Revenue | $319.92M |
| Gross Profit | $545.72M |
| R&D Expenses | $194.03M |
| SG&A Expenses | $514.85M |
| Operating Expenses | $708.87M |
| Operating Income | -$163.15M |
| Net Income | -$60.02M |
| EPS (Basic) | $-0.85 |
| EPS (Diluted) | $-0.91 |
| Shares Outstanding (Basic) | 66.19M |
| Shares Outstanding (Diluted) | 66.19M |
Key Highlights
- 1Total net sales increased by 26.8% to $863.4 million in fiscal year 2021, demonstrating strong top-line growth.
- 2The Software and Sensors segment significantly outpaced the TASER segment in growth, increasing revenue by 35.6% year-over-year, driven by Axon Evidence and cloud services.
- 3Despite revenue growth, the company reported a net loss of $60.0 million for fiscal year 2021, a substantial increase from the $1.7 million net loss in 2020, largely due to a significant rise in stock-based compensation expenses.
- 4The company has a substantial backlog of $2.4 billion as of December 31, 2021, primarily within the Software and Sensors segment, indicating strong future revenue potential.
- 5Axon is investing heavily in its future, planning capital expenditures of $135-$160 million for 2022, including a new manufacturing facility and expansion of TASER device capacity.
- 6Supply chain constraints impacted fulfillment of certain orders in 2021, with approximately $35.0 million for TASER 7 devices and $15.5 million for Axon Body 3 devices deferred to 2022.
- 7The company's stock performance significantly outperformed major indices from 2016 to 2021, indicating strong historical investor returns.